INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 12, Issue 10- 2025

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.10.004

Machine-Assisted Diagnostic Algorithms for Sickle Cell Anemia: From Newborn Screening to Adult Risk Stratification

***Emmanuel Ifeanyi Obeagu**
Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.
*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com,
ORCID: 0000-0002-4538-0161

Abstract

Sickle cell anemia (SCA) is a prevalent hereditary hemoglobinopathy associated with significant morbidity and mortality worldwide. Early diagnosis and accurate risk stratification are essential for optimizing clinical outcomes. Recent advances in machine-assisted diagnostic algorithms offer the potential to enhance traditional approaches by integrating hematologic, genetic, imaging, and clinical data. These algorithms can support automated newborn screening, predict disease severity, identify patients at risk for complications, and guide personalized therapeutic strategies. This narrative review examines current developments in machine-assisted diagnostics for SCA, highlighting applications from early detection in neonates to risk stratification in adults. Challenges related to data quality, resource limitations, clinical integration, and ethical considerations are also discussed. By synthesizing current evidence, this review underscores the transformative potential of algorithm-driven approaches in precision diagnosis and management of SCA, paving the way for more timely and tailored interventions across the patient lifespan.

Keywords: Sickle cell anemia, machine learning, diagnostic algorithms, newborn screening, risk stratification

Introduction

Sickle cell anemia (SCA) is a hereditary hemoglobinopathy caused by a mutation in the β-globin gene, resulting in the production of abnormal hemoglobin S. This molecular defect leads to chronic hemolytic anemia, recurrent vaso-occlusive crises, and progressive multi-organ damage, contributing to significant morbidity and mortality. Globally, SCA affects millions, with the highest prevalence in sub-Saharan Africa, the Middle East, India, and among populations of African descent worldwide. Despite advances in management, delayed diagnosis remains a major challenge, particularly in resource-limited settings, where access to early screening and comprehensive care is often restricted [1-2].Early identification of SCA is critical for implementing preventive and therapeutic interventions, such as penicillin prophylaxis, vaccination, hydroxyurea therapy, and regular monitoring for organ complications. Conventional diagnostic approaches, including hematologic assays, hemoglobin electrophoresis, and molecular testing, have been effective in detecting the disease and its variants. However, these methods are labor-intensive, dependent on specialized laboratory infrastructure, and limited in their ability to predict disease severity or long-term complications [3-4].

The emergence of machine-assisted diagnostic algorithms offers a transformative approach to SCA detection and management. By leveraging computational models—including machine learning (ML) and artificial intelligence (AI)—clinicians can integrate complex datasets encompassing hematologic parameters, genetic profiles, imaging findings, and clinical histories. These algorithms can identify subtle patterns not readily apparent to human observers, enabling automated newborn screening, genotype classification, risk stratification, and individualized treatment planning [5-6].Machine-assisted diagnostics also hold the potential to optimize resource allocation and clinical decision-making. Predictive models can identify high-risk patients for early intervention, monitor disease progression, and guide therapy adjustments, reducing morbidity and improving quality of life. Additionally, digital platforms and algorithm-driven workflows can enhance data standardization, facilitate real-time clinical support, and strengthen population-level SCA surveillance [7-8].This narrative review examines the current landscape of machine-assisted diagnostic algorithms for SCA, highlighting applications in newborn screening, genetic subtype discrimination, and adult risk stratification. We explore the integration of hematologic, genetic, and imaging markers into multi-modal algorithms, discuss implementation challenges, and outline future directions for precision diagnostics in SCA management. By synthesizing emerging evidence, this review aims to provide a comprehensive perspective on how algorithm-driven strategies can advance early detection and personalized care for patients with SCA across the lifespan.

Hematologic Markers and Algorithmic Screening

Hematologic evaluation remains the cornerstone of SCA detection and serves as a primary input for algorithmic diagnostic pathways. Key laboratory parameters—including complete blood count (CBC), reticulocyte count, hemoglobin electrophoresis, and high-performance liquid chromatography (HPLC)—provide essential information on red blood cell morphology, hemoglobin composition, and hematologic abnormalities associated with SCA. In neonates, these tests can detect the presence of hemoglobin S and differentiate between sickle cell trait and disease, enabling timely initiation of prophylactic care [9-11].Machine-assisted algorithms enhance traditional hematologic screening by integrating multiple parameters to improve diagnostic accuracy and reduce human error. Supervised machine learning models, trained on large datasets of hematologic profiles, can identify patterns that distinguish SCA from other hemoglobinopathies or anemia types. For example, algorithms can analyze red cell indices such as mean corpuscular volume, hemoglobin

concentration, and reticulocyte percentage to predict disease severity or anticipate complications, including vaso-occlusive crises and early organ dysfunction [12-14].

Beyond diagnosis, algorithmic analysis of hematologic trends supports longitudinal monitoring and risk stratification. Predictive models can flag patients with deteriorating hematologic profiles, prompting early clinical intervention. This approach is particularly valuable in low-resource settings, where automated hematologic screening can reduce reliance on specialist interpretation and improve coverage in population-wide newborn screening programs [15-16].Integration of hematologic data into machine-assisted workflows lays the foundation for multi-modal diagnostic pathways, bridging laboratory findings with genetic, imaging, and clinical data to create comprehensive, individualized risk profiles for patients with SCA. By enabling early, accurate, and automated detection, hematologic markers serve as a critical entry point for algorithm-driven management strategies that span from infancy to adulthood [17-18].

Genetic Diagnostics: Definitive Confirmation and Subtype Stratification

Genetic testing remains the definitive method for diagnosing sickle cell anemia (SCA) and distinguishing among its various subtypes. The disease arises from a point mutation in the β-globin gene (HBB), resulting in the substitution of valine for glutamic acid at the sixth position of the β-globin chain. This molecular change gives rise to hemoglobin S, which underlies the pathophysiology of sickling, hemolysis, and vaso-occlusion [19-20].Traditional molecular diagnostic techniques, including polymerase chain reaction (PCR), restriction fragment length polymorphism analysis, and DNA sequencing, enable precise identification of the HbS allele and related variants such as HbC, HbE, and rare compound heterozygotes. These tests not only confirm disease presence but also facilitate genotype-based risk stratification, guiding treatment decisions and long-term prognosis [21].

Machine-assisted diagnostic algorithms enhance genetic evaluation by integrating genotype data with hematologic, imaging, and clinical information. For instance, predictive models can correlate specific genetic variants with disease severity, likelihood of complications, and response to therapies such as hydroxyurea or chronic transfusion. Deep learning models trained on large genomic datasets can also identify rare mutations and compound heterozygous patterns that might otherwise be overlooked, improving diagnostic precision and personalized care [22-23].Genetic diagnostics serve as a critical component in multi-modal algorithmic pathways, providing definitive confirmation while informing clinical management. By combining molecular data with other diagnostic inputs, machine-assisted approaches can create comprehensive patient profiles, enabling individualized risk assessment and early therapeutic intervention. This integration ensures that genotype information is not interpreted in isolation but contributes meaningfully to holistic, algorithm-driven SCA care [23-24].

Imaging Markers: Early Detection of Organ Stress

SCA is characterized not only by hematologic abnormalities but also by progressive organ damage that can remain clinically silent in early stages. Subclinical injury frequently affects the spleen, kidneys, liver, lungs, and central nervous system, and early detection is critical for preventing irreversible complications. Imaging modalities provide a non-invasive means to identify these changes before overt clinical manifestations appear, offering valuable input for algorithm-driven diagnostic pathways [25].Doppler ultrasonography, echocardiography, and magnetic resonance imaging (MRI) are commonly employed to detect structural and functional abnormalities in SCA patients. For example, transcranial Doppler (TCD) ultrasonography can identify elevated cerebral blood flow velocities, a strong predictor of stroke risk in children. Renal ultrasonography and MRI can reveal early nephropathy, while echocardiography may detect early pulmonary

hypertension or cardiac remodeling associated with chronic hemolysis [26-27].

Machine-assisted algorithms enhance imaging diagnostics through automated pattern recognition and quantitative analysis. Deep learning models can detect subtle changes in organ morphology, tissue perfusion, or flow dynamics that may escape conventional interpretation. By integrating imaging findings with hematologic and genetic data, predictive models can stratify patients according to risk, enabling preemptive interventions such as transfusion therapy, hydroxyurea initiation, or closer monitoring for organ complications [28-29].The integration of imaging markers into multi-modal algorithmic frameworks thus facilitates early, precise, and personalized detection of organ stress in SCA. This approach complements hematologic and genetic diagnostics, forming a comprehensive foundation for risk prediction, longitudinal monitoring, and individualized management strategies across the lifespan of patients [30].

Towards Integrated Algorithmic Pathways: A Multi-Modal Approach

The complexity of SCA requires a diagnostic approach that extends beyond single-modality assessment. While hematologic, genetic, and imaging markers each provide valuable insights, their integration into a cohesive, machine-assisted algorithmic pathway offers the greatest potential for early detection, risk stratification, and personalized care. Multi-modal algorithms leverage data from multiple sources to generate comprehensive patient profiles, enabling predictive analytics and clinical decision support [31-32].In practice, an integrated pathway begins with hematologic screening, which can flag potential SCA cases through red blood cell indices and hemoglobin patterns. Positive findings are confirmed through genetic diagnostics, providing definitive diagnosis and subtype classification. Imaging markers then complement these data by revealing early organ stress, even in asymptomatic patients, while longitudinal clinical data further inform risk prediction for complications such as stroke, pulmonary hypertension, or renal impairment [33].

Machine learning models can synthesize these diverse data streams, identify complex patterns, and generate individualized risk scores. For example, a predictive algorithm could combine hematologic trends, genetic variants, and transcranial Doppler velocities to forecast stroke risk in pediatric patients, guiding timely preventive interventions. In adults, integrated pathways can support monitoring for organ dysfunction, optimize therapy adjustments, and prioritize high-risk individuals for specialized care [35].This multi-modal framework also enhances operational efficiency, particularly in resource-limited settings. By automating data analysis and prioritizing high-risk patients, integrated algorithms reduce the burden on healthcare providers, improve diagnostic coverage, and facilitate consistent, evidence-based clinical decision-making. Ultimately, these pathways exemplify the transformative potential of combining hematologic, genetic, and imaging data through machine-assisted algorithms to advance precision diagnostics and individualized management in SCA [36].

Challenges and Considerations in Implementation

Despite the promise of machine-assisted diagnostic algorithms for sickle cell anemia (SCA), several challenges must be addressed to ensure effective and equitable implementation.

Data Quality and Standardization: The accuracy of algorithmic predictions depends on high-quality, standardized datasets. Variability in laboratory measurements, incomplete clinical records, and population-specific genetic differences can compromise model performance. Ensuring consistent data collection and validation across diverse healthcare settings is essential for reliable outcomes [37].

Resource Limitations: Many regions with a high SCA burden, particularly in sub-Saharan Africa and low-resource areas, face constraints in

laboratory infrastructure, imaging capabilities, and computational resources. Limited access to high-throughput genetic testing or advanced imaging may hinder the deployment of sophisticated algorithmic systems.

Clinical Integration: Algorithms must complement—not replace—clinical expertise. Successful implementation requires physician training, workflow adaptation, and effective communication of algorithm outputs to support informed decision-making. Resistance to adopting new technologies or reliance on "black-box" models can also impede integration [38].

Ethical and Regulatory Considerations: Patient privacy, data security, and equitable access are critical concerns. Algorithms must be transparent, interpretable, and validated for diverse populations to prevent unintended disparities in care. Additionally, regulatory frameworks for AI-driven diagnostics are still evolving and require alignment with clinical practice standards.

Sustainability and Maintenance: Continuous model updates, retraining with new data, and long-term maintenance are necessary to preserve algorithm accuracy and relevance. Without sustainable infrastructure and funding, algorithmic tools may become outdated or underutilized.

Conclusion

Machine-assisted diagnostic algorithms represent a transformative approach to the early detection, subtype classification, and risk stratification of sickle cell anemia (SCA). By integrating hematologic, genetic, imaging, and clinical data, these multi-modal pathways enable precise, individualized, and proactive patient management across the lifespan—from newborn screening to adult care. While challenges related to data quality, resource limitations, clinical integration, and ethical considerations remain, ongoing advances in computational medicine and machine learning offer promising solutions.

The adoption of algorithm-driven diagnostics has the potential to improve early identification of at-risk patients, optimize therapy, prevent complications, and enhance overall outcomes. Future efforts should focus on validating these models in diverse populations, ensuring equitable access, and embedding algorithmic tools seamlessly into clinical workflows. By bridging traditional diagnostics with advanced computational approaches, integrated algorithms can pave the way toward precision medicine and more effective, personalized care for patients living with SCA.

References

1. Ansari, J., Moufarrej, Y. E., Pawlinski, R., &Gavins, F. N. E. (2018). Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. *Expert review of hematology*, *11*(1), 45–55. https://doi.org/10.1080/17474086.2018.1407240
2. Obeagu, E. I., &Olateju, O. R. (2025). Integrating sickle cell disease care into primary healthcare in Uganda: a narrative review. *Annals of medicine and surgery (2012)*, *87*(9), 5918–5924. https://doi.org/10.1097/MS9.0000000000003713
3. McGann, P. T., & Hoppe, C. (2017). The pressing need for point-of-care diagnostics for sickle cell disease: A review of current and future technologies. *Blood cells, molecules & diseases*, *67*, 104–113. https://doi.org/10.1016/j.bcmd.2017.08.010
4. Obeagu E. I. (2025). Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. *Annals of medicine and surgery (2012)*, *87*(6), 3279–3288. https://doi.org/10.1097/MS9.0000000000002981
5. Hippisley-Cox, J., & Coupland, C. A. (2025). Development and external validation of prediction algorithms to improve early diagnosis of cancer. *Nature communications*, *16*(1), 3660. https://doi.org/10.1038/s41467-025-57990-5

6. Obeagu E. I. (2025). Thrombosis risk in sickle cell disease with HIV co-infection: unraveling the complex interactions and clinical implications - a narrative review. *Annals of medicine and surgery (2012)*, *87*(8), 5070–5076. https://doi.org/10.1097/MS9.0000000000003533
7. Chong, P. L., Vaigeshwari, V., Mohammed Reyasudin, B. K., Noor Hidayah, B. R. A., Tatchanaamoorti, P., Yeow, J. A., & Kong, F. Y. (2025). Integrating artificial intelligence in healthcare: applications, challenges, and future directions. *Future science OA*, *11*(1), 2527505. https://doi.org/10.1080/20565623.2025.2527505
8. Obeagu E. I. (2025). Clotting, inflammation, and immunity: the multifaceted role of platelets in HIV and sickle cell disease - a narrative review. *Annals of medicine and surgery (2012)*, *87*(9), 5878–5886. https://doi.org/10.1097/MS9.0000000000003677
9. Arishi, W. A., Alhadrami, H. A., &Zourob, M. (2021). Techniques for the Detection of Sickle Cell Disease: A Review. *Micromachines*, *12*(5), 519. https://doi.org/10.3390/mi12050519
10. Obeagu E. I. (2025). Adhesion molecules in focus: mechanistic pathways and therapeutic avenues in sickle cell vaso-occlusion - a narrative review. *Annals of medicine and surgery (2012)*, *87*(9), 5775–5783. https://doi.org/10.1097/MS9.0000000000003619
11. Carden, M. A., Fasano, R. M., & Meier, E. R. (2020). Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia. *Blood reviews*, *40*, 100637. https://doi.org/10.1016/j.blre.2019.100637
12. Meier, E. R., Wright, E. C., & Miller, J. L. (2014). Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the Cooperative Study of Sickle Cell Disease. *American journal of hematology*, *89*(9), 904–906. https://doi.org/10.1002/ajh.23777
13. Higgins J. M. (2015). Red blood cell population dynamics. *Clinics in laboratory medicine*, *35*(1), 43–57. https://doi.org/10.1016/j.cll.2014.10.002
14. Obeagu E. I. (2025). Public-private partnerships in tackling sickle cell disease in Uganda: a narrative review. *Annals of medicine and surgery (2012)*, *87*(6), 3339–3355. https://doi.org/10.1097/MS9.0000000000003082
15. Liu, J., Gou, Y., Yang, W., Wang, H., Zhang, J., Wu, S., Liu, S., Tao, T., Tang, Y., Yang, C., Chen, S., Wang, P., Feng, Y., Zhang, C., Liu, S., Peng, X., & Zhang, X. (2025). Development and application of machine learning models for hematological disease diagnosis using routine laboratory parameters: a user-friendly diagnostic platform. *Frontiers in medicine*, *12*, 1605868. https://doi.org/10.3389/fmed.2025.1605868
16. Obeagu E. I. (2025). Hypoxia, Inflammation, and Cytokine Crosstalk in Sickle Cell Disease: From Mechanisms to Modulation- A Narrative Review. *Pediatric health, medicine and therapeutics*, *16*, 217–225. https://doi.org/10.2147/PHMT.S544217
17. Asad, S., Ahmed, I., & Ali, N. (2017). Utility of Peripheral Film Findings and its Correlation with Automated Analyzer - An Audit from Tertiary Care Hospital. *Journal of laboratory physicians*, *9*(1), 1–4. https://doi.org/10.4103/0974-2727.189233
18. Mbayabo, G., LumbalaKabuyi, P., Ngole, M., Lumaka, A., Race, V., Maisin, D., Gruson, D., Matthijs, G., Minga, T. M., Devriendt, K., Van Geet, C., &Tshilobo, P. L. (2022). Value of DNA testing in the diagnosis of sickle-cell anemia in childhood in an environment with a high prevalence of other causes of anemia. *Journal of clinical laboratory analysis*, *36*(8), e24593. https://doi.org/10.1002/jcla.24593
19. Arishi, W. A., Alhadrami, H. A., &Zourob, M. (2021). Techniques for the Detection of Sickle Cell Disease: A Review. *Micromachines*, *12*(5), 519. https://doi.org/10.3390/mi12050519

20. Yang, N., Zhang, H., Han, X., Liu, Z., & Lu, Y. (2024). Advancements and applications of loop-mediated isothermal amplification technology: a comprehensive overview. *Frontiers in microbiology*, *15*, 1406632. https://doi.org/10.3389/fmicb.2024.1406632
21. Figueiredo M. S. (2015). The compound state: Hb S/beta-thalassemia. *Revistabrasileira de hematologia e hemoterapia*, *37*(3), 150–152. https://doi.org/10.1016/j.bjhh.2015.02.008
22. Ozgüç M. (2011). Genetic testing: predictive value of genotyping for diagnosis and management of disease. *The EPMA journal*, *2*(2), 173–179. https://doi.org/10.1007/s13167-011-0077-y
23. Kalpatthi, R., &Novelli, E. M. (2018). Measuring success: utility of biomarkers in sickle cell disease clinical trials and care. *Hematology. American Society of Hematology. Education Program*, *2018*(1), 482–492. https://doi.org/10.1182/asheducation-2018.1.482
24. Jordan, L. C., Roberts Williams, D. O., Rodeghier, M. J., Covert Greene, B. V., Ponisio, M. R., Casella, J. F., McKinstry, R. C., Noetzel, M. J., Kirkham, F. J., Meier, E. R., Fuh, B., McNaull, M., Sarnaik, S., Majumdar, S., McCavit, T. L., & DeBaun, M. R. (2018). Children with sickle cell anemia with normal transcranial Doppler ultrasounds and without silent infarcts have a low incidence of new strokes. *American journal of hematology*, *93*(6), 760–768. https://doi.org/10.1002/ajh.25085
25. Vancauwenberghe, T., Snoeckx, A., Vanbeckevoort, D., Dymarkowski, S., &Vanhoenacker, F. M. (2015). Imaging of the spleen: what the clinician needs to know. *Singapore medical journal*, *56*(3), 133–144. https://doi.org/10.11622/smedj.2015040
26. Qhalib, H. A., & Zain, G. H. (2014). Hepatobiliary Complications of Sickle Cell Disease among Children Admitted to Al Wahda Teaching Hospital, Aden, Yemen. *Sultan Qaboos University medical journal*, *14*(4), e556–e560.
27. Czap, A. L., &Sheth, S. A. (2021). Overview of Imaging Modalities in Stroke. *Neurology*, *97*(20 Suppl 2), S42–S51. https://doi.org/10.1212/WNL.0000000000012794
28. Gao, X., Lv, Q., & Hou, S. (2023). Progress in the Application of Portable Ultrasound Combined with Artificial Intelligence in Pre-Hospital Emergency and Disaster Sites. *Diagnostics (Basel, Switzerland)*, *13*(21), 3388. https://doi.org/10.3390/diagnostics13213388
29. Arishi, W. A., Alhadrami, H. A., &Zourob, M. (2021). Techniques for the Detection of Sickle Cell Disease: A Review. *Micromachines*, *12*(5), 519. https://doi.org/10.3390/mi12050519
30. Olupot-Olupot, P., Connon, R., Kiguli, S., Opoka, R. O., Alaroker, F., Uyoga, S., Nakuya, M., Okiror, W., Nteziyaremye, J., Ssenyondo, T., Nabawanuka, E., Kayaga, J., Williams Mukisa, C., Amorut, D., Muhindo, R., Frost, G., Walsh, K., Macharia, A. W., Gibb, D. M., Walker, A. S., … Williams, T. N. (2022). A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa. *American journal of hematology*, *97*(5), 527–536. https://doi.org/10.1002/ajh.26492
31. Uçucu, S., Karabıyık, T., &Azik, F. (2022). Difficulties in the diagnosis of HbS/beta thalassemia: Really a mild disease?.*Journal of medical biochemistry*, *41*(1), 32–39. https://doi.org/10.5937/jomb0-30420
32. Cetinic, I., de Lange, C., Lagerstrand, K., Kindblom, J. M., Sjögren, L., &Hebelka, H. (2025). Applicability of multiple quantitative ultrasound liver biomarkers in children and adolescents with severe obesity. *BMC pediatrics*, *25*(1), 390. https://doi.org/10.1186/s12887-025-05750-1
33. Obeagu E. I. (2025). Sickle cell anemia and social justice: a pathway to equitable healthcare in Uganda. *Annals of medicine and surgery (2012)*, *87*(11), 7283–7293. https://doi.org/10.1097/MS9.0000000000003910

34. Ally, M., &Balandya, E. (2023). Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa. *Seminars in hematology*, *60*(4), 192–199. https://doi.org/10.1053/j.seminhematol.2023.08.002
35. Heidt, B., Siqueira, W. F., Eersels, K., Diliën, H., van Grinsven, B., Fujiwara, R. T., &Cleij, T. J. (2020). Point of Care Diagnostics in Resource-Limited Settings: A Review of the Present and Future of PoC in Its Most Needed Environment. *Biosensors*, *10*(10), 133. https://doi.org/10.3390/bios10100133
36. Ghoneim, A. M. E., Mohamed, S. K., Hetta, W. A., &Alkaphoury, M. G. (2025). Role of transcranial Doppler ultrasound in early assessment of acute post-traumatic brain injury. *Medicine*, *104*(42), e45171. https://doi.org/10.1097/MD.0000000000045171
37. Zhang, B., Wan, Z., Luo, Y., Zhao, X., Samayoa, J., Zhao, W., & Wu, S. (2025). Multimodal integration strategies for clinical application in oncology. *Frontiers in pharmacology*, *16*, 1609079. https://doi.org/10.3389/fphar.2025.1609079
38. Boardman, F. K., Clark, C., Jungkurth, E., & Young, P. J. (2020). Social and cultural influences on genetic screening programme acceptability: A mixed-methods study of the views of adults, carriers, and family members living with thalassemia in the UK. *Journal of genetic counseling*, *29*(6), 1026–1040. https://doi.org/10.1002/jgc4.1231

Access this Article in Online	
Quick Response Code	Website: www.ijcrcps.com
	Subject: Haematology
DOI: 10.22192/ijcrcps.2025.12.10.004	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2025). Machine-Assisted Diagnostic Algorithms for Sickle Cell Anemia: From Newborn Screening to Adult Risk Stratification. Int. J. Curr. Res. Chem. Pharm. Sci. 12(10): 34-41.
DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.10.004

